Akèy › Anemi Refraktè ak Eksè Blast › Washington
Etid klinik pou Anemi Refraktè ak Eksè Blast nan Washington
5 etid pou Anemi Refraktè ak Eksè Blast ap chèche patisipan nan sit nan Washington.
Vil nan Washington
Tèks ofisyèl etid la (Anglè)
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03670966211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03128034A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Seattle Cancer Care Alliance, Seattle
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT04256317A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 2
Laj 18 a 66 · Tout sèks · Mizajou Mar 17, 2026 · NCT06859424HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Fred Hutchinson Cancer Research Center, Seattle
Ap rekriteFaz 2
3 Months · Tout sèks · Mizajou Nov 12, 2025 · NCT02143830Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.